NCT02004522View on ClinicalTrials.gov

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

PHASE3CompletedINTERVENTIONAL
Enrollment

319

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 19, 2017

Study Completion Date

June 30, 2021

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Duvelisib

PI3K Inhibitor

DRUG

Ofatumumab

monoclonal antibody

Trial Locations (92)

1000

Brussels

1023

Auckland

1083

Budapest

1090

Vienna

1122

Budapest

1130

Vienna

1200

Brussels

3000

Leuven

3002

East Melbourne

3058

Melbourne

4032

Debrecen

4442

Palmerston North

4600

Wels

5042

Bedford Park

6725

Szeged

7400

Kaposvár

7624

Pécs

9000

Ghent

9024

Győr

9100

Sint-Niklaas

10032

New York

10065

New York

10707

Berlin

14033

Caen

18057

Rostock

20132

Milan

20162

Milan

22903

Charlottesville

26789

Leer

28033

Madrid

28050

Madrid

31008

Pamplona

32605

Gainesville

32701

Altamonte Springs

32763

Orange City

32778

Tavares

32806

Orlando

33076

Bordeaux

33511

Brandon

33607

Tampa

33705

St. Petersburg

33761

Clearwater

33777

Largo

33916

Fort Myers

33980

Port Charlotte

33990

Cape Coral

34119

Naples

34209

Bradenton

34223

Englewood

34236

Sarasota

34292

Venice

34453

Inverness

34608

Spring Hill

34655

New Port Richey

34667

Hudson

35033

Rennes

35128

Padua

37203

Nashville

41017

Crestview Hills

44000

Nantes

45014

Fairfield

45236

Cincinnati

47014

Meldola

47923

Rimini

48121

Ravenna

50937

Cologne

54511

Vendœuvres

63100

Clermont-Ferrand

63130

St Louis

73100

Lecce

80218

Denver

85025

La Roche-sur-Yon

87042

Limoges

89081

Ulm

93009

Bobigny

95107

Argenteuil

95124

Catania

92093-0698

La Jolla

34135-4529

Bonita Springs

02114

Boston

02115

Boston

07601

Hackensack

08903

New Brunswick

00133

Roma

08035

Barcelona

08036

Barcelona

08041

Barcelona

BH7 7DW

Bournemouth

LS9 7TF

Leeds

M20 4BX

Manchester

NG5 1PB

Nottingham

OX3 7JL

Oxford

All Listed Sponsors
lead

SecuraBio

INDUSTRY

NCT02004522 - A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | Biotech Hunter | Biotech Hunter